Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • DeepTek Medical...

    DeepTek Medical Imaging collaborates with Japanese MBM for AI- lead solution to screen Coronavirus

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-04-05T11:00:05+05:30  |  Updated On 5 April 2020 11:00 AM IST
    DeepTek Medical Imaging collaborates with Japanese MBM for AI- lead solution to screen Coronavirus

    Pune: Recently there have been notable developments in health tech diagnostics due to Artificial Intelligence tools for analyzing medical scans like X-Ray, CT, and MRI. In this era where a shortage of radiologists is felt globally - Artificial Intelligence (AI) lead solutions are assisting in improving reporting quality, reduce turnaround time while helping to make medical image reading services more accessible and affordable.

    DeepTek Medical Imaging Pvt. Ltd. (a Pune - India based technology venture; Managing Director - Ajit Patil) and MDM Inc. (Tokyo - Japan-based medical technology venture; Representative - Chie Akusawa) announced a collaborative research and development initiative towards developing an AI-based solution for the screening of COVID-19 (Novel Coronavirus) using chest radiography.

    DeepTek has already deployed a similar population screening solution for Tuberculosis (TB) screening. It instantaneously processes chest radiographs to identify potential TB and other infections. This solution has been used for public health screening of over 75,000 individuals in India. DeepTek's TB solution is also being leveraged in the APAC region. Over 1.2 million people die of TB annually.

    WHO is working on a mission to stop the TB epidemic by the year 2030; while India has set up a target of the year 2025. With the rapid spread of the new COVID-19 infection globally, MBM Inc. has taken an initiative towards developing a similar solution that can help reduce stress on healthcare professionals and enable better patient care.

    The solution will process chest radiographs to screen a subclass of the broader condition of pneumonia using deep learning algorithms. This can be helpful in screening for epidemics and pandemics like the COVID-19, SARS, H1N1 outbreaks in appropriate clinical settings. The solution is expected to be available for trials from early May 2020.

    MBM is a Japanese company conducting R&D and sales of AI systems for medical use. MBM is an IBM partner in Japan. DeepTek's medical AI solution will be installed in the MBM's and AI image diagnosis support device which it plans to sell in Japan from this year and explore global opportunities in the years to follow.

    Read also: Coronavirus: Zydus Wellness launches hand sanitizer under Nycil brand to meet growing demand

    deeptekcoronaviruscovid-19ajit-patil
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok